Biomarin Pharmaceutical is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $51.77 – . Biomarin Pharmaceutical employs 3,040 staff and has a trailing 12-month revenue of around $3.1 billion.
Offer valid from 12/15/25 through 1/2/26. Customer must fund their Active Invest account with at least $50 within 45 days of opening the account. Receive a minimum of $15. Probability of member receiving $3,000 is a probability of 0.026% If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Percentages for the $3,000 are subject to decrease. See full terms and conditions.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link See full terms and For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
d19c0be9-29b6-4644-a071-32c476ff5e24-Up to 2% match bonus
Up to 2% match bonus
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Biomarin Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Biomarin Pharmaceutical stock undervalued or overvalued?
Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biomarin Pharmaceutical's P/E ratio
Biomarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Biomarin Pharmaceutical shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Biomarin Pharmaceutical's PEG ratio
Biomarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6236. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biomarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Biomarin Pharmaceutical's EBITDA
Biomarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $794 million.
The EBITDA is a measure of a Biomarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
Biomarin Pharmaceutical financials
Revenue TTM
$3.1 billion
Gross profit TTM
$2.5 billion
Return on assets TTM
6.15%
Return on equity TTM
9.07%
Profit margin
16.82%
Book value
$31.53
Market Capitalization
$10.2 billion
TTM: trailing 12 months
Biomarin Pharmaceutical's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biomarin Pharmaceutical.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Biomarin Pharmaceutical's total ESG risk score
Total ESG risk: 25.92
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biomarin Pharmaceutical's overall score of 25.92 (as at 12/31/2018) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Biomarin Pharmaceutical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Biomarin Pharmaceutical's environmental score
Environmental score: 0.12/100
Biomarin Pharmaceutical's environmental score of 0.12 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Biomarin Pharmaceutical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Biomarin Pharmaceutical's social score
Social score: 15.87/100
Biomarin Pharmaceutical's social score of 15.87 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Biomarin Pharmaceutical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Biomarin Pharmaceutical's governance score
Governance score: 7.42/100
Biomarin Pharmaceutical's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Biomarin Pharmaceutical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Biomarin Pharmaceutical's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Biomarin Pharmaceutical scored a 1 out of 5 for controversy – the highest score possible, reflecting that Biomarin Pharmaceutical has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Biomarin Pharmaceutical Inc was last rated for ESG on: 2019-01-01.
Total ESG score
25.92
Total ESG percentile
42.26
Environmental score
0.12
Environmental score percentile
1
Social score
15.87
Social score percentile
1
Governance score
7.42
Governance score percentile
1
Level of controversy
1
Biomarin Pharmaceutical share dividends
We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.
Biomarin Pharmaceutical share price volatility
Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $50.76 up to $73.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.298. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).
Biomarin Pharmaceutical overview
BioMarin Pharmaceutical Inc. , a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U. S.
Frequently asked questions
null What percentage of Biomarin Pharmaceutical is owned by insiders or institutions? Currently 0.767% of Biomarin Pharmaceutical shares are held by insiders and 98.005% by institutions.How many people work for Biomarin Pharmaceutical? Latest data suggests 3,040 work at Biomarin Pharmaceutical.When does the fiscal year end for Biomarin Pharmaceutical? Biomarin Pharmaceutical's fiscal year ends in December.Where is Biomarin Pharmaceutical based? Biomarin Pharmaceutical's address is: 770 Lindaro Street, San Rafael, CA, United States, 94901What is Biomarin Pharmaceutical's ISIN number? Biomarin Pharmaceutical's international securities identification number is: US09061G1013What is Biomarin Pharmaceutical's CUSIP number? Biomarin Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 09061G101
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
